Sensitivity of MRI Tumor Biomarkers to VEGFR Inhibitor Therapy in an Orthotopic Mouse Glioma Model
Figure 3
Cediranib therapy decreases tumor T2, but does not affect ADC.
(left) While a significant decrease in ADC was observed for cediranib treated mice (p = 0.01) after 2–3 days of treatment, no statistically significant difference was observed between cediranib and control groups for the change over time of ADC. (right) In contrast, the decreased T2 observed after 2–3 days of treatment for cediranib animals was significantly (p<0.01) different from the increased T2 observed for control animals.